Abstract: This work presents generalized forgetting recursive least squares (GF-RLS), a generalization of RLS that encompasses many extensions of RLS as special cases. First, sufficient conditions are ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Jennifer Way received funding from NSW Department of Education, Strategic Research Fund (2021–2024). ID: G212850. Katherin Cartwright received funding from NSW Department of Education, Strategic ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Microsoft’s Copilot generative AI is popping up on the web, in mobile apps, in the Edge browser, and especially in Windows. But just what exactly is it? Here’s everything you need to know. I've been ...

Word already displays the number of words in a document in its status bar for all versions. This number appears at the bottom, second to the right after the number of pages in the document. If you ...

Soon to be the official tool for managing Python installations on Windows, the new Python Installation Manager picks up where the ‘py’ launcher left off. Python is a first-class citizen on Microsoft ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...